Digital Health

Roche Acquires Rest of Foundational Medicine for $2.4B to Enhance Precision Medicine

Roche Acquires Rest of Foundational Medicine for .4B to Enhance Precision Medicine

Roche, today announced it has acquire all of the outstanding shares in Foundation Medicine that is not already owned by Roche and its affiliates for $2.4B, representing $137 per share. Together, the companies will leverage expertise in genomics and molecular information to enhance the development of perdsonalized medicines and care for patients with cancer.

Foundation Medicine, based in Cambridge, Massachusetts, is a market leading molecular information company dedicated to a transformation in cancer care, where each patient’s treatment is informed by a deep understanding of the molecular changes that contribute to their disease. Their services include a full suite of comprehensive genomic profiling (CGP) assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials.

Upon closing, the acquisition focuses on integrating Foundation Medicine’s high quality comprehensive genomic profiling (CGP) testing and innovative data services to realise Roche’s vision of personalized healthcare. Foundation Medicine (FMI) will continue its operations as a separate and autonomous legal entity.

“Foundation Medicine and Roche share the philosophy that every cancer patient should have access to personalized care informed by validated molecular information. Joining forces with Roche as an independent operating company allows Foundation Medicine to continue its collaboration with Roche, as well as our biopharma partners, to drive ubiquitous access to CGP testing and innovative data services,” said Troy Cox, Chief Executive Officer for Foundation Medicine.

The acquisition is expected to take place in the second half of 2018.